ImmunoGenes (Hungary)
This technology was patented in 2007 and from that point on the company had two main characteristics: developing custom made antibodies and developing transgenic animals. Our goal is to support R&D of pharma companies and academics to improve their efficiency in identifying new therapeutic targets and therapeutic candidates. We believe that we can change the monoclonal antibody development in most casee even if you have a target that seems impossible.
Basic Information
- Category: Business
- Founded: 2008
- Headquarters: Budakeszi
- Website: http://immunogenes.com/
Documented Facts
- Email: imre.kacskovics@immunogenes.com (No linked source recorded for this statement.)
- Founded: 2008 (No linked source recorded for this statement.)
- Website: http://immunogenes.com/ (No linked source recorded for this statement.)
- Headquarters: Budakeszi (No linked source recorded for this statement.)
- Country: Hungary (No linked source recorded for this statement.)
Evidence and Sources
- ImmunoGenes (Hungary) — Official Website (official)
Citation Guidance
Explore Business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about ImmunoGenes (Hungary).
- Canonical profile: https://brandsource.ai/brands/immunogenes-hungary
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/immunogenes-hungary/json-ld
- Citation profile API: https://brandsource.ai/api/brands/immunogenes-hungary/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (86/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-23
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
This technology was patented in 2007 and from that point on the company had two main characteristics: developing custom made antibodies and developing transgenic animals. Our goal is to support R&D of pharma companies and academics to improve their efficiency in identifying new therapeutic targets and therapeutic candidates. We believe that we can change the monoclonal antibody development in most casee even if you have a target that seems impossible.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 5 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.